The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spach, K. M.
Right arrow Articles by Hayes, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spach, K. M.
Right arrow Articles by Hayes, C. E.
The Journal of Immunology, 2006, 177: 6030-6037.
Copyright © 2006 by The American Association of Immunologists, Inc.

IL-10 Signaling Is Essential for 1,25-Dihydroxyvitamin D3-Mediated Inhibition of Experimental Autoimmune Encephalomyelitis1

Karen M. Spach*, Faye E. Nashold{dagger}, Bonnie N. Dittel{ddagger} and Colleen E. Hayes2,{dagger}

* Department of Nutritional Sciences and {dagger} Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin, Madison, WI 53706; and {ddagger} Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53226


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Multiple sclerosis (MS) results from an aberrant, neuroantigen-specific, T cell-mediated autoimmune response. Because MS prevalence and severity decrease sharply with increasing sunlight exposure, and sunlight supports vitamin D3 synthesis, we proposed that vitamin D3 and 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) may protect against MS. In support of this hypothesis, 1,25-(OH)2D3 strongly inhibited experimental autoimmune encephalomyelitis (EAE). This inhibition required lymphocytes other than the encephalitogenic T cells. In this study, we tested the hypothesis that 1,25-(OH)2D3 might inhibit EAE through the action of IL-10-producing regulatory lymphocytes. We report that vitamin D3 and 1,25-(OH)2D3 strongly inhibited myelin oligodendrocyte peptide (MOG35–55)-induced EAE in C57BL/6 mice, but completely failed to inhibit EAE in mice with a disrupted IL-10 or IL-10R gene. Thus, a functional IL-10-IL-10R pathway was essential for 1,25-(OH)2D3 to inhibit EAE. The 1,25-(OH)2D3 also failed to inhibit EAE in reciprocal, mixed bone marrow chimeras constructed by transferring IL-10-deficient bone marrow into irradiated wild-type mice and vice versa. Thus, 1,25-(OH)2D3 may be enhancing an anti-inflammatory loop involving hemopoietic cell-produced IL-10 acting on brain parenchymal cells and vice versa. If this interpretation is correct, and humans have a similar bidirectional IL-10-dependent loop, then an IL-10-IL-10R pathway defect could abrogate the anti-inflammatory and neuro-protective functions of sunlight and vitamin D3. In this way, a genetic IL-10-IL-10R pathway defect could interact with an environmental risk factor, vitamin D3 insufficiency, to increase MS risk and severity.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Multiple sclerosis (MS)3 shows a striking gradient of increasing prevalence with increasing latitude (1). Worldwide studies have attributed this gradient to a strong link between low sunlight exposure and high MS risk (2, 3, 4, 5). Because sunlight exposure produces vitamin D3 (6), we hypothesized that the high MS risk with low sunlight exposure might reflect insufficient sunlight-catalyzed vitamin D3 synthesis to support the immunoregulatory functions of the vitamin D3 hormone, 1,25-dihydroxyvitamin D3 (7).

Consistent with this hypothesis, 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) strongly inhibited experimental autoimmune encephalomyelitis (EAE), an MS model (8, 9). The 1,25-(OH)2D3-mediated inhibition of EAE required Rag-1-dependent lymphocytes other than the encephalitogenic CD4+ T cells (10). To explain this result, we hypothesized that 1,25-(OH)2D3 might strengthen the function of lymphocytes that regulate potentially autoreactive T cell responses (10). The CD4+CD25+ lymphocytes that suppress EAE do so via an IL-10-dependent mechanism (11, 12, 13, 14). IL-10 is a potent inhibitor of APC function, inflammatory T cell activation, cytokine synthesis, and chemokine synthesis (15). Increases in spinal cord IL-10 correlated with EAE remissions (16). Mice with transgenic IL-10 resisted EAE (17), whereas mice with a disrupted IL-10 gene were highly EAE susceptible (18, 19). These data indicate that the IL-10-IL-10R pathway has very important suppressor functions in EAE.

The present experiments evaluated vitamin D3- and 1,25-(OH)2D3-mediated protection from myelin oligodendrocyte peptide (MOG35–55)-induced EAE in C57BL/6 (B6) mice with targeted disruptions of the IL-10 or IL-10R genes to test the hypothesis that the inhibition mechanism might be IL-10 dependent. Having established that the IL-10-IL-10R pathway was essential, we also evaluated irradiation bone marrow (BM) chimeras to pinpoint the source of the essential IL-10. Furthermore, we investigated a possible direct effect of the hormone on IL-10 or IL-10R expression. We present a model for a bidirectional, IL-10-dependent, anti-inflammatory loop to explain how vitamin D may implement sunlight’s protective biological effects in MS, and discuss the implications of this model for vitamin D-based preventive and therapeutic strategies in MS.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

We purchased the B6, B6.SJL-Ptprca Pep3b/BoyJ (B6.CD45.1), and C57BL/6-Il10tm1Cgn mice (B6.IL-10–/–) from The Jackson Laboratory. Genentech donated the CFR2.4 (B6.IL-10Rbeta–/–) breeder mice; they were genotyped for the loss of IL-10Rbeta and the acquisition of neo as described (20). Mice were housed in our pathogen-free mouse colony at 23°C with 40–60% humidity, 12-h light-dark cycles, and ad libitum access to water. Before experiments, they were fed Lab Diet no. 5008 (PMI Nutrition International) containing 0.33 µg/day vitamin D3 and 1% calcium. Experiments used male and female mice aged 6–8 wk (age- and sex-matched within experiments). The Institutional Animal Care and Use Committee approved all of the experimental protocols.

Antigens

The MOG35–55 was purchased from BioSynthesis and had the amino acid sequence MEVGWYRSPFSRVVHLYRNGK.

Vitamin D3 or 1,25-(OH)2D3 treatment and EAE induction

A nutritionally complete synthetic diet was formulated as we described (21), except that vitamin D was omitted. The vitamin D3 (Sigma-Aldrich) was added to this diet in an amount to provide 1 µg/day. Alternatively, the 1,25-(OH)2D3 (Sigma-Aldrich) was added in an amount to provide 50 ng/day to females and 100 ng/day to males. These doses significantly inhibited EAE in previous studies (9, 10, 22, 23, 24, 25, 26). Fresh diet was provided three times per week. For prevention studies, mice were fed the synthetic diets before EAE induction (10). For treatment studies, EAE was induced in chow-fed mice, and at the peak of disease, 200 ng of 1,25-(OH)2D3 in oil or oil only as the placebo was injected i.p (27). EAE was induced and clinical EAE severity was assessed daily exactly as described (10). Blood samples were obtained before EAE induction and at the end of the study.

Histopathology

For histopathological evaluation, mice were euthanized and perfused with saline. The spinal cords were removed, divided into six equal segments, frozen in OCT compound (Sakura Finetek). And sectioned transversely (10 µm). The cryosections were fixed in 4% paraformaldehyde, stained with Gill’s no. 3 H&E Y (Sigma Diagnostics), and examined using a Zeiss Axioskop microscope equipped with a Plan-Neofluar x20/0.5 objective. Bright field images were acquired with AxioVision 3.0 software controlling an Axiocam digital camera. For the histopathology analysis, each of six sections per mouse was divided into quadrants, and each quadrant was scored in a blinded fashion as 0 or 1, based on the absence or presence, respectively, of infiltrating inflammatory cells. The histopathology score was recorded as the percentage of spinal cord quadrants that showed a readily identifiable inflammatory cell infiltrate.

Serum calcium analysis

Blood was collected, clotted, and centrifuged (2000 x g for 10 min) at 6°C. The serum was decanted and stored at –20°C. The samples, standards, and buffer blanks (2 µl each) were aliquoted into duplicate wells of a 96-well plate. The calcium detection reagent was prepared according to the manufacturer’s directions (Sigma Diagnostics), and 0.25 ml was added to each well. The absorbance at 570 nm less the blank was measured 10 to 30 min later. The Ca2+ mM/L serum was determined from a standard curve.

Real-time PCR

Real-time PCR was performed as described (28) with minor modifications (29). In brief, total RNA was extracted using TRI Reagent (Molecular Research Center) and reverse transcribed from an oligo(dT) primer using the Reverse Transcription System (Promega). Real-time PCR was performed with SYBRGreen PCR Master Mix (Applied Biosystems) in a GeneAmp 5700 Sequence Detection System. Purified and quantified control cDNA was serially diluted, and amplified in each run; the control cDNA vs the threshold cycle formed a standard curve. The transcript abundance, determined with the aid of the standard curve, is reported relative to GAPDH. Published primers for the GAPDH and IFN-{gamma} (30), and for Foxp3 (31) were used. The IL-10 primers were 5'-CCC TTT GCT ATG GTG TCC TT-3' and 5'-TGG TTT CTC TTC CCA AGA CC-3'; they were designed with Primer Express (Applied Biosystems).

Flow cytometry

For flow cytometric studies, PBS perfusion was done and single-cell suspensions of spinal cord cells or splenocytes were prepared as described (10, 32). In brief, dissociated spleen cells in cold staining buffer (5% heat-inactivated FBS and 0.1% sodium azide in PBS, pH 7.3) were depleted of RBC, and stained (106 cells/sample) for 30–40 min on ice with predetermined optimal amounts of FITC-, PE-, or allophycocyanin-conjugated mAb. Spinal cord cells were centrifuged through a Percoll gradient, washed, and stained as previously described (10). Reference samples were stained with fluorochrome-coupled isotype control mAb, or single-color specific mAb stains for compensation. Stained samples were analyzed on a FACSCalibur (BD Biosciences) using CellQuest software. The fluorescent mAbs to IFN-{gamma}, IL-10, IL-10R, CD4, CD11b, CD25, CD45.2, and CD45.1 were purchased from Southern Biotechnology Associates or BD Biosciences.

Intracellular staining for cytokines

To enumerate cytokine-producing cells, EAE was induced, and when the placebo-treated mice reached stage 2 EAE (20 days post MOG immunization), all mice were euthanized, and the spinal cord and cervical lymph node cells were collected and analyzed (33). The cells were stimulated overnight with immobilized Abs to CD3, cultured 4 h with monensin, washed, and stained with FITC-coupled Abs to CD4 or isotype control Abs. The stained cells were paraformaldehyde-fixed, permeabilized in buffer with 0.01% Triton X-100, and stained with PE-coupled Abs to IFN-{gamma} and allophycocyanin-coupled Abs to IL-10 or isotype control Abs (BD Pharmingen). Flow cytometric data were acquired on a FACSCalibur using CellQuest software (BD Biosciences).

Irradiation BM chimeras

Irradiation BM chimeras were constructed by a standard protocol (34, 35). In brief, recipient mice (6 wk of age) were given antibiotics in the drinking water for 3 days, irradiated with a total of 1200 rad (2 doses 4 h apart), injected i.v. with 2–5 x 106 BM cells, and maintained in a sterile environment with antibiotics for 2 wk. Thereafter, they were maintained under standard conditions without antibiotics. At 6–7 wk posttransplantation, blood lymphocytes were stained and analyzed for CD45.1 and CD45.2 to quantify donor BM engraftment. At 7 wk posttransplantation, the mice were placed on the 1,25-(OH)2D3-supplemented or placebo control diet. At 8 wk posttransplantation, EAE was induced and evaluated as above.

Statistical analysis

Individual mice were analyzed and the mean and SD were calculated for each group of mice. Experiments were repeated at least once. The group sizes are given in the table and figure legends. The significance of differences between the group means was determined using the Mann-Whitney U test (n ≤16), Student’s t test (n > 16), or {chi}2 test (binomial data) as indicated (36); p < 0.05 was considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Vitamin D3 inhibited EAE in wild-type (Wt) but not IL-10–/– mice

The experiments reported here used MOG35–55-induced EAE in B6 mice to investigate why Rag-1-dependent lymphocytes other than the neuroantigen-reactive CD4 T cells were needed for 1,25-(OH)2D3 to inhibit EAE (10). To test the hypothesis that the vitamin D3 system might be enhancing the function of IL-10-producing regulatory lymphocytes, we studied vitamin D3-mediated inhibition of MOG35–55-induced EAE in mice with a Wt or disrupted IL-10 gene. Mice were fed synthetic diets that provided 0 (–D diet) or 1 µg/day (+D diet) of vitamin D3 beginning at age 4 wk exactly as described (26). At age 8 wk, the +D mice had 56 ± 3 nM/L serum 25-hydroxyvitamin D3, whereas the –D mice had 8 ± 3 nM/L. All mice were then primed with MOG35–55 and evaluated for EAE disease. The +D diet significantly reduced the incidence, peak clinical score, and cumulative disease index for MOG35–55-induced EAE in female but not male B6 mice (Table I). These results confirm the female-specific protective effect of dietary vitamin D3 that we reported previously for MBP-induced EAE in B10.PL mice (26). However, the +D diet did not inhibit MOG35–55-induced EAE in B6.IL-10–/– mice (Table I). We conclude that vitamin D3-mediated inhibition of EAE requires IL-10 gene expression.


View this table:
[in this window]
[in a new window]
  		Table I. The vitamin D3 reduced the incidence and severity of EAE in female B6 mice, but not in male B6 mice or B6.IL-10–/– mice of either gendera

 
1,25-(OH)2D3 inhibited EAE in Wt but not IL-10–/– mice

One explanation for the failure of vitamin D3 to inhibit EAE in B6.IL-10–/– mice could be an unanticipated requirement for IL-10 to stimulate the conversion of the biologically inactive vitamin D3 and 25-hydroxyvitamin D3 compounds into the biologically active hormone, 1,25-(OH)2D3. To bypass a possible vitamin D3 metabolism problem in B6.IL-10–/– mice, we repeated the experiment except that biologically active 1,25-(OH)2D3 was used in place of vitamin D3. The 1,25-(OH)2D3-fed male and female B6 had a lower EAE incidence (p < 0.001), decreased mortality (p < 0.05), and lower peak severity and cumulative disease index (p < 0.0001) than the placebo-fed controls (Fig. 1A and Table II). Histopathology showed that the 1,25-(OH)2D3-fed B6 mice had lesions with inflammatory cell infiltration in 17% of the microscopic fields examined, whereas the placebo-fed controls had lesions in >60% of the fields (Fig. 2). The 1,25-(OH)2D3-treated B6 mice also had 66% fewer spinal cord IFN-{gamma} transcripts than the placebo-treated controls, as determined by real-time PCR (Table III). In contrast, the 1,25-(OH)2D3-treated and placebo-treated mice had equivalent numbers of IFN-{gamma}-producing CD4+ Th1 cells in the lymph nodes (placebo, 16 ± 5%; 1,25-(OH)2D3, 16 ± 6%). Collectively, the clinical, histological, and immunological data establish that 1,25-(OH)2D3 inhibits MOG35–55-induced EAE in B6 mice, as it does MBP-induced EAE in B10.PL mice (9, 10, 29).


Figure 1
View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 1. Functional IL-10 and IL-10R genes were required for 1,25(OH)2D3-mediated inhibition of EAE. A, Clinical EAE disease in B6 mice. Adult female and male mice were fed synthetic diets formulated to provide 0 ({square}), or 50 ng/day (females) or 100 ng/day (males) ({blacksquare}) of 1,25(OH)2D3 for 5 days. EAE was induced with MOG35–55 peptide, synthetic diet feeding was continued, and disease severity was scored daily. B, Clinical disease in B6.IL-10–/– mice. C, Clinical disease in B6.IL-10R–/– mice. The cumulative mean from three separate experiments is shown in A and B (22 mice/group up to day 23; 10 mice/group after day 23). The mean from one of two experiments is shown in C (6 mice/group). From day 14 onward, the B6 mice fed 1,25-(OH)2D3 had significantly less severe EAE than all other groups (p < 0.05; Mann-Whitney U test).

 

View this table:
[in this window]
[in a new window]
  		Table II. The 1,25-(OH)2D3 delayed the onset and reduced the severity of EAE in B6 but not B6.IL-10–/– or B6.IL-10R–/– micea

 

Figure 2
View larger version (143K):
[in this window]
[in a new window]
  		FIGURE 2. Dietary 1,25-(OH)2D3 reduced the inflammatory cell infiltration and lesion formation associated with EAE in B6 but not B6.IL-10–/– or B6.IL-10R–/– mice. The experiment was performed as described in the Fig. 1 legend. Spinal cord samples (three per group) were obtained on day 22 post-MOG injection and a histopathological analysis was performed. Representative H&E-stained sections are shown. The nuclei of infiltrating, inflammatory cells appear dark blue. The percentage of sections with lesions (in parentheses) in the 1,25-(OH)2D3-treated B6 mice differed significantly (p < 0.05; Mann-Whitney U test) from all other groups.

 

View this table:
[in this window]
[in a new window]
  		Table III. Supplementary 1,25-(OH)2D3 inhibited IFN-{gamma} production in the CNS of B6 but not B6.IL-10–/– micea

 
In contrast, the 1,25-(OH)2D3 did not inhibit MOG35–55-induced EAE in B6.IL-10–/– mice (Fig. 1 and Table II). The incidence, onset, mortality, peak disease severity, and cumulative disease index were not significantly different for 1,25-(OH)2D3-fed and placebo-fed B6.IL-10–/– mice. Furthermore, the 1,25-(OH)2D3-fed and placebo-fed B6.IL-10–/– mice had equivalent histopathology (Fig. 2) with >60% of the fields showing inflammatory lesions. Lastly, the two groups had equally high numbers of IFN-{gamma} transcripts in the spinal cord (Table III). The 1,25-(OH)2D3 also inhibited MBP-induced EAE in Wt B10.PL mice, but not B10.PL mice lacking IL-10 gene expression, confirming these results (data not shown). We conclude that a functional IL-10 gene is necessary for 1,25-(OH)2D3 to inhibit EAE.

The precise mechanism for 1,25-(OH)2D3-mediated inhibition of EAE is debated. It was recently suggested that elevated serum calcium may be necessary and sufficient to inhibit EAE in female mice, and that 1,25-(OH)2D3 may have no functional role other than to elevate serum calcium (37). To investigate this point, we analyzed serum calcium before and during the study shown in Fig. 1. The serum calcium levels were equivalent in all groups before the study (Table IV). The 1,25-(OH)2D3-treated B6 mice had no increase in the serum calcium on day 0, but elevated serum calcium by day 53. Therefore, elevated calcium correlated with decreased EAE in these mice. However, the 1,25-(OH)2D3-treated B6.IL-10–/– mice had a significant increase in serum calcium on day 0, and a further increase by day 53 (Table IV), but no decrease in any measure of EAE disease (Table II). Thus, elevated serum calcium was not sufficient to inhibit EAE in the B6.IL-10–/– female mice. Moreover, the high vitamin D3 diet inhibited all measures of EAE disease in females without causing hypercalcemia (Table I and Ref. 26). Thus elevated serum calcium was neither necessary nor sufficient to inhibit EAE.


View this table:
[in this window]
[in a new window]
  		Table IV. Long-term 1,25-(OH)2D3 supplementation resulted in elevated serum calcium levels without concomitant EAE inhibition in mice with a disrupted IL-10 genea

 
1,25-(OH)2D3 did not inhibit EAE in IL-10R–/– mice

We reasoned that a fully functional IL-10-IL-10R pathway might be necessary for 1,25-(OH)2D3 to inhibit EAE. To test this hypothesis, we repeated the prevention study using B6.IL-10Rbeta–/– mice (with a nonfunctional IL-10Rbeta-signaling chain) in place of B6.IL-10–/– mice (20). The results showed that 1,25-(OH)2D3 did not inhibit MOG35–55-induced EAE in B6.IL-10Rbeta–/– mice (Fig. 1C). The EAE incidence, onset, mortality, peak disease severity, and cumulative disease index were not significantly different for 1,25-(OH)2D3-fed and placebo-fed B6.IL-10Rbeta–/– mice (Table II). Collectively, our data show for the first time that the CNS-specific, 1,25-(OH)2D3-activated, neuroprotective mechanism depends on a functional IL-10-IL-10R pathway.

1,25-(OH)2D3 did not alter IL-10 or IL-10R in the CNS

We next looked for possible 1,25-(OH)2D3-mediated enhancement of IL-10 gene expression. The experiment shown in Fig. 1A was repeated, and the IL-10-producing CD4+ T cells were analyzed by flow cytometry 28 days postimmunization. The IL-10-producing CD4+ T cells in the CNS cell suspension were too infrequent to measure. In the cervical lymph node cell suspension, the two groups had equivalent IL-10-producing CD4+ T cell percentages (placebo, 15 ± 8%; 1,25-(OH)2D3, 12 ± 4%) and fluorescence intensities (data not shown). Furthermore, when 1,25-(OH)2D3 or a placebo was administered to mice with acute EAE, the spinal cord and the lymph nodes had equivalent IL-10 transcripts 6-h posttreatment (placebo 0.4 ± 0.2 and 1,25-(OH)2D3 0.3 ± 0.1 IL-10 transcripts per 103 GAPDH transcripts). We have shown that direct, 1,25-(OH)2D3-mediated changes in gene expression can be detected using the 6 h treatment (29). Thus, neither protein nor transcript studies showed 1,25-(OH)2D3-mediated enhancement of IL-10 synthesis. However, the data do not rule out 1,25-(OH)2D3-mediated effects on minor cell populations like regulatory lymphocytes.

We also looked for 1,25-(OH)2D3-mediated enhancement of IL-10R gene expression. The 1,25-(OH)2D3 or a placebo was administered to mice with acute EAE, and flow cytometry was performed on spinal cord cells collected 6 h later. We have established that no hormone-mediated changes in the CNS cell populations occur within this time period (29). The nonimmunized control mice had microglial cells expressing an intermediate level of CD11b and the IL-10R (Fig. 3A) (38, 39, 40). The placebo-treated mice with EAE had the CD11bintIL-10R+ microglial cells, plus a CD11b+IL-10R– cell population not found in the nonimmunized control mice (Fig. 3B). These CD11b+IL-10R– myeloid lineage cells appear to be infiltrating, activated macrophages. To our knowledge, this is the first report that CNS-infiltrating, activated macrophages do not express the IL-10R. We found no differences in the IL-10R+ or IL-10R– cell percentages or the IL-10R density between the two treatment groups (Fig. 3, B and C, and data not shown). Thus, we found no evidence for a direct effect of 1,25-(OH)2D3 on IL-10R expression. However, we cannot rule out effects on minor cell populations like regulatory lymphocytes, astrocytes, or neurons that are not represented in the cell suspension.


Figure 3
View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 3. The 1,25-(OH)2D3 had no rapid, direct effect on IL-10R expression in the inflamed CNS. A, Spinal cord cells from a nonimmune control mouse. B, Spinal cord cells from a mouse that had EAE and was placebo treated. C, Spinal cord cells from a mouse that had EAE and was treated with 1,25-(OH)2D3. B6 mice with MOG35–55-induced EAE (clinical score 2.5–3.0) were injected with a placebo or with 1,25-(OH)2D3. Six hours later, the spinal cord cells were collected, and separated on a Percoll gradient, stained with fluorescent Ab to CD11b and to IL-10R. Cells in the live cell gate were analyzed by flow cytometry for CD11b and IL-10R expression. The results shown are representative of two separate experiments with four to five female and male mice per group. The samples from the experimental mice with EAE were compared with the naive control sample; *, p < 0.05 (Mann-Whitney U test).

 
Regulatory CD4+CD25+ T cells that express Foxp3 and suppress EAE by an IL-10-dependent mechanism have been described (11, 12, 13, 14, 41, 42, 43). To see whether 1,25-(OH)2D3 increased Foxp3, the prevention study was repeated, and spinal cord Foxp3 transcripts/103 GAPDH transcripts were quantified 4 wk postimmunization. The placebo (24 ± 6) and 1,25-(OH)2D3-fed mice (29 ± 17) had equivalent Foxp3 transcripts, ruling out direct effects on Foxp3.

Reciprocal BM chimera studies

Having established that a functional IL-10-IL-10R pathway is necessary for the 1,25-(OH)2D3-activated protective mechanism, we next sought to determine the source of the essential IL-10. The T and B lymphocytes, infiltrating macrophages, microglial cells, and astrocytes all have the capacity to produce IL-10 (15, 44). Reciprocal irradiation BM chimeras were constructed by transferring Wt BM into lethally irradiated, IL-10–/– recipients (B6.CD45.1->B6.IL-10–/–) and vice versa (B6.IL-10–/–->B6.CD45.1). Cells with a Wt IL-10 gene carried the CD45.1 allotype, whereas cells with an IL-10–/– genotype carried the CD45.2 allotype as described (34, 35). Control B6.CD45.1->B6 and B6.IL-10–/–->B6.IL-10–/– chimeras were also constructed. At 6 wk post-BM transplantation, PBLs were >85% donor origin. At the end of each study, the splenocytes and splenic CD3+ T cells were 85–91% donor origin (Table V and data not shown). These CD45 allotype data indicated that all animals were chimeras.


View this table:
[in this window]
[in a new window]
  		Table V. The 1,25-(OH)2D3 inhibited EAE only if the radio-sensitive hemopoietic cells and the radio-resistant brain parenchymal cells were capable of producing IL-10a

 
Chimeric mice were fed synthetic diets with or without 1,25-(OH)2D3, immunized with MOG35–55, and evaluated for EAEdisease. As expected, the 1,25-(OH)2D3-treated B6.CD45.1->B6 mice had a lower incidence of EAE, a later onset, a lower peak clinical score, and a lower cumulative disease index than the placebo-treated B6.CD45.1->B6 mice (Fig. 4A and Table V). Also as expected, the 1,25-(OH)2D3-treated and placebo-treated B6.IL-10–/–->B6.IL-10–/– mice did not differ in the incidence of EAE, the day of onset, the peak clinical score, or the cumulative disease index (Fig. 4B and Table V). These data confirm that a functional IL-10-IL-10R pathway is necessary for 1,25-(OH)2D3-mediated protection from EAE.


Figure 4
View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 4. Radiosensitive hemopoietic cells and radioresistant brain parenchymal cells must express IL-10 for 1,25(OH)2D3-mediated inhibition of EAE. Female B6.IL-10–/– or B6.CD45.1 BM was transferred into irradiated B6.CD45.1 or B6.IL-10–/– female mice to produce four chimeras: B6.CD45.1->B6 (A); B6.IL-10–/–->B6.IL-10–/– (B); B6.CD45.1->B6.IL-10–/– (C); and B6.IL-10–/–->B6.CD45.1 (D). The chimeric mice were fed synthetic diets containing 0 ({circ}) or 50 ng/day (•) 1,25(OH)2D3 for 5 days. Eight weeks posttransplantation, EAE was induced with MOG35–55 peptide, synthetic diet feeding was continued, and disease severity was scored daily. The cumulative mean from two separate experiments is shown (10–12 mice/group). On days 13 and 14, the B6.IL-10–/–->B6.CD45.1 mice had significantly more severe EAE than the B6.CD45.1->B6.IL-10–/– mice, regardless of the diet group (p < 0.05; Mann-Whitney U test). Other differences were not significant.

 
Most of the chimeric mice with limited IL-10 gene expression developed such severe and rapidly progressive EAE disease that the experiment was terminated 15 days post immunization. The placebo-treated B6.IL-10–/–->B6.CD45.1 chimeric mice had significantly more severe clinical EAE disease on days 13 and 14, and a higher cumulative EAE disease index on day 15, than the placebo-treated B6.CD45.1->B6.IL-10–/– chimeric mice. These data suggest that hemopoietic cell-produced IL-10 is especially critical for protection from EAE.

Surprisingly, the 1,25-(OH)2D3 did not inhibit EAE in B6.CD45.1->B6.IL-10–/– or B6.IL-10–/–->B6.CD45.1 mice (Fig. 4, C and D; Table V). Thus, limiting IL-10 synthesis to either the radio-sensitive or the radio-resistant cells abrogated 1,25-(OH)2D3-mediated protection. These data suggest that IL-10 synthesis from both cell types is essential for optimal 1,25-(OH)2D3-mediated protection. In fact, there may be an anti-inflammatory amplification loop involving bidirectional IL-10 signaling.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The present experiments investigated how vitamin D3 and 1,25-(OH)2D3 inhibit EAE induction, in an effort to understand how this sunlight-derived hormone might mediate sunlight’s protective effects in MS. The results supported the hypothesis that the protective mechanism requires a functional IL-10-IL-10R pathway. The vitamin D3 and 1,25-(OH)2D3 inhibited MOG35–55-induced EAE in B6 female mice, and 1,25-(OH)2D3 also inhibited EAE in male mice, consistent with our published data on MBPAc1–11-induced EAE in B10.PL female and male mice (9, 26). Importantly, our data show for the first time that vitamin D3 and 1,25-(OH)2D3 failed to inhibit EAE in B6 mice with targeted disruptions of either the IL-10 or the IL-10R genes. Extending this finding, we also show that 1,25-(OH)2D3 failed to inhibit EAE in reciprocal BM chimeric mice with restricted IL-10 gene expression. These studies suggest that both the radio-sensitive hemopoietic cells and the radio-resistant brain parenchymal cells must contribute IL-10 for optimal 1,25-(OH)2D3-mediated protection. Others reported that adding 1,25-(OH)2D3 and dexamethasone to cultures of D011.10 transgenic T cells with APC and peptide increased the frequency of IL-10-producing, regulatory T cells (12). However, our data showed no 1,25-(OH)2D3-induced increases in Foxp3 transcripts as a marker of regulatory T cells in the CNS. It is possible that the 1,25-(OH)2D3 stimulated IL-10-producing regulatory cells that do not express Foxp3. Our data also did not show an effect of 1,25-(OH)2D3 on IL-10 or IL-10R expression in freshly explanted spinal cord cells. However, these data do not rule out an effect on regulatory lymphocytes, astrocytes, or neurons that would have comprised <5% of the cell suspension.

Several caveats apply to our interpretation of the present data. First, we may have missed minor IL-10-independent protective effects of the 1,25-(OH)2D3, if the major protective activities were IL-10 dependent and determined the experimental results. We may also have missed IL-10-independent protective effects occurring at a later stage of EAE than was studied here. With respect to the chimera studies, because chimerism was 85–91%, a small percentage of the hemopoietic cells in the B6.IL-10–/–->B6.CD45.1 chimeric mice had the Wt IL-10 gene. Furthermore, because a minor percentage of microglial cells in irradiation BM chimeras derived from hemopoietic stem cells (45, 46), some brain parenchymal cells in the B6.CD45.1->B6.IL-10–/– chimeric mice would likely have had the Wt IL-10 gene. Nevertheless, in both cases, the IL-10 producers were insufficient to enable 1,25-(OH)2D3-mediated protection, further supporting the concept of a bidirectional IL-10 amplification loop.

To envision how an 1,25-(OH)2D3-activated, IL-10- and IL-10R-dependent, Rag-1-dependent protective mechanism could limit encephalitogenic CD4+ Th1 cells in the CNS, it is important to consider which CNS cells produce IL-10, and how IL-10 protects the CNS during inflammation. The major IL-10-producing brain parenchymal cells are the microglial cells and astrocytes (44, 47). The IL-10 promotes neuron and glial cell survival by blocking apoptotic signaling. More specifically, IL-10R stimulation regulates the Jak1/Stat3, PI3-kinase, MAP-kinase, suppressor of cytokine signaling (SOCS), and NF-{kappa}B life- and death-signaling pathways, ultimately inhibiting both proapoptotic cytokine-induced and mitochondrial-induced apoptosis in neurons and glial cells. The IL-10 also blocks proinflammatory cytokine induction and signaling. Specifically, IL-10R-mediated activation of SOCS reduces proinflammatory cytokine synthesis and cytokine receptor expression and activation. Finally, IL-10 inhibits costimulation of brain-infiltrating T cells via the CD28-CD80/86 pathway, thereby favoring anergy induction.

A model explaining how a 1,25-(OH)2D3-activated, IL-10- and IL-10R-dependent, Rag-1-dependent protective mechanism could limit encephalitogenic CD4+ Th1 cell activation in the CNS must also take into account which cells express the vitamin D receptor (VDR) (48). Myeloid cells, lymphoid cells, astrocytes, microglial cells, neurons, and oligodendrocytes all express the VDR (reviewed in (49). The T cells and type 2 astrocytes increase their VDR expression when activated, whereas the myeloid lineage cells diminish their VDR expression when activated (49). Our present and previous data rule out a direct effect of 1,25-(OH)2D3 on APCs and on naive encephalitogenic CD4+ T cells in the absence of additional Rag-1-dependent lymphocytes in the EAE model (10). Therefore, it is most likely that the 1,25-(OH)2D3 acted directly on regulatory lymphocytes and/or on CNS-resident cells like astrocytes, neurons, and/or microglia. The requirement for IL-10 gene expression in both hemopoietic cells and brain parenchymal cells suggests that 1,25-(OH)2D3 may be acting on both types of cells. The model that is most consistent with our data is bi-directional IL-10 signaling. The 1,25-(OH)2D3 could act directly on regulatory lymphocytes to increase their IL-10-dependent suppressive functions, and the regulatory lymphocyte-produced IL-10 could act on the brain parenchymal cells, altering their function such that they stimulate potentially encephalitogenic, autoreactive T cells to apoptose or to become anergic. To complete the bi-directional IL-10-signaling, the 1,25-(OH)2D3 could also be acting directly on the brain parenchymal cells to increase their IL-10-dependent suppressive functions. Further experimentation will be required to test this model. In particular, it will be important to demonstrate that there are direct effects of the 1,25-(OH)2D3 on regulatory lymphocytes and on brain parenchymal cells like neurons, astrocytes, and microglia that result in an immunosuppressive environment in the CNS.

Given the importance of IL-10 for the protection of the CNS during inflammation (44), it is not surprising that IL-10 deficiency correlates strongly with susceptibility to EAE and MS. The IL-10-deficient mice were highly susceptible to EAE (18, 19). Similarly, IL-10 deficiency appears to be an MS risk factor in humans. The IL-10-secreting T cell frequency was lower in MS patients than controls (50). Also, MS patients had less serum IL-10 protein (51), blood cell IL-10 mRNA (52, 53, 54), and blood cell IL-10 protein (55) than controls. Finally, the IL-10 allele with the low expresser promoter polymorphism was more common in MS patients than controls (56, 57). These correlations suggest a possible cause and effect relationship between IL-10 deficiency and EAE in mice and MS in humans.

Our data showing that IL-10 deficiency in mice eliminated the protective effects of 1,25-(OH)2D3 in EAE has very important implications for MS. Specifically, our data suggest that IL-10 deficiency in humans may diminish the protective effects of sunlight and vitamin D3 in MS-susceptible individuals. There may be synergy between a genetic MS risk factor, IL-10 deficiency, and an environmental MS risk factor, insufficient vitamin D3 synthesis due to inadequate sunlight exposure, increasing the risk of MS by compromising regulatory lymphocyte functions. If this hypothesis is correct, then it will be important to correct the IL-10 deficiency in MS-susceptible individuals for sunlight and vitamin D3 prevention and treatment strategies to be beneficial.


   Acknowledgments
 
We acknowledge Sir E. Donald Acheson (International Centre for Health and Society University College London) for extended and fruitful discussions on the vitamin D-MS hypothesis, and how a genetic IL-10-IL-10R pathway defect could interact with an environmental risk factor, vitamin D3 insufficiency, to increase MS risk or severity in the human population. We are also indebted to Dr. Julie Olson (Department of Neurological Surgery, University of Wisconsin Medical School) for critically reading the manuscript. We thank Anna M. Rothert for technical assistance with the irradiation BM chimera studies, and Wayne Nehls for animal husbandry.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Multiple Sclerosis Society Research Grant RG-3107 and National Institutes of Health Predoctoral Training Grant DK 07665-08 through the Department of Nutritional Sciences (University of Wisconsin, Madison, WI) (to K.M.S). Back

2 Address correspondence and reprint requests to Dr. Colleen E. Hayes, Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin, 433 Babcock Drive, Madison, WI 53706. E-mail address: hayes{at}biochem.wisc.edu Back

3 Abbreviations used in this paper: MS, multiple sclerosis, 1,25-(OH)2D3, 1,25-dihydoxyvitamin D3; BM, bone marrow; EAE, experimental autoimmune encephalomyelitis; MBP, myelin basic protein; MOG35–55, myelin oligodendrocytic glycoprotein peptide; VDR, vitamin D receptor. Back

Received for publication December 20, 2005. Accepted for publication August 15, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Ebers, G. C., A. D. Sadovnick. 1993. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology 12: 1-5. [Medline]
  2. Acheson, E. D., C. A. Bachrach, F. M. Wright. 1960. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiatr. 35: (Suppl. 147):132-147.
  3. Hammond, S. R., D. R. English, J. G. McLeod. 2000. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 123: 968-974. [Abstract/Free Full Text]
  4. Freedman, D. M., M. Dosemeci, M. C. Alavanja. 2000. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup. Environ. Med. 57: 418-421. [Abstract/Free Full Text]
  5. van der Mei, I. A., A. L. Ponsonby, T. Dwyer, L. Blizzard, R. Simmons, B. V. Taylor, H. Butzkueven, T. Kilpatrick. 2003. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Br. Med. J. 327: 316[Abstract/Free Full Text]
  6. Holick, M. F.. 2003. Vitamin D: A millennium perspective. J. Cell. Biochem. 88: 296-307. [Medline]
  7. Hayes, C. E., M. T. Cantorna, H. F. DeLuca. 1997. Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 216: 21-27. [Abstract]
  8. Lemire, J. M., D. C. Archer. 1991. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87: 1103-1107. [Medline]
  9. Cantorna, M. T., C. E. Hayes, H. F. DeLuca. 1996. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 93: 7861-7864. [Abstract/Free Full Text]
  10. Nashold, F. E., K. A. Hoag, J. Goverman, C. E. Hayes. 2001. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D3 prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 119: 16-29. [Medline]
  11. Stohlman, S. A., L. Pei, D. J. Cua, Z. Li, D. R. Hinton. 1999. Activation of regulatory cells suppresses experimental allergic encephalomyelitis via secretion of IL-10. J. Immunol. 163: 6338-6344. [Abstract/Free Full Text]
  12. Barrat, F. J., D. J. Cua, A. Boonstra, D. F. Richards, C. Crain, H. F. Savelkoul, R. de Waal-Malefyt, R. L. Coffman, C. M. Hawrylowicz, A. O’Garra. 2002. In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195: 603-616. [Abstract/Free Full Text]
  13. Sundstedt, A., E. J. O’Neill, K. S. Nicolson, D. C. Wraith. 2003. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J. Immunol. 170: 1240-1248. [Abstract/Free Full Text]
  14. Zhang, X., D. N. Koldzic, L. Izikson, J. Reddy, R. F. Nazareno, S. Sakaguchi, V. K. Kuchroo, H. L. Weiner. 2004. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int. Immunol. 16: 249-256. [Abstract/Free Full Text]
  15. Moore, K. W., R. de Waal Malefytqq, R. L. Coffman, A. O’Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765. [Medline]
  16. Kennedy, M. K., D. S. Torrance, K. S. Picha, K. M. Mohler. 1992. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149: 2496-2505. [Abstract]
  17. Cua, D. J., H. Groux, D. R. Hinton, S. A. Stohlman, R. L. Coffman. 1999. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 189: 1005-1010. [Abstract/Free Full Text]
  18. Samoilova, E. B., J. L. Horton, Y. Chen. 1998. Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery. Cell. Immunol. 188: 118-124. [Medline]
  19. Bettelli, E., M. P. Das, E. D. Howard, H. L. Weiner, R. A. Sobel, V. K. Kuchroo. 1998. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161: 3299-3306. [Abstract/Free Full Text]
  20. Spencer, S. D., F. Di Marco, J. Hooley, S. Pitts-Meek, M. Bauer, A. M. Ryan, B. Sordat, V. C. Gibbs, M. Aguet. 1998. The orphan receptor CRF2–4 is an essential subunit of the interleukin 10 receptor. J. Exp. Med. 187: 571-578. [Abstract/Free Full Text]
  21. Smith, S. M., N. S. Levy, C. E. Hayes. 1987. Impaired immunity in vitamin A-deficient mice. J. Nutr. 117: 857-865. [Abstract/Free Full Text]
  22. Cantorna, M. T., W. D. Woodward, C. E. Hayes, H. F. DeLuca. 1998. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta1 and IL-4. J. Immunol. 160: 5314-5319. [Abstract/Free Full Text]
  23. Cantorna, M. T., J. Humpal-Winter, H. F. DeLuca. 1999. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J. Nutr. 129: 1966-1971. [Abstract/Free Full Text]
  24. Mattner, F., S. Smiroldo, F. Galbiati, M. Muller, P. Di Lucia, P. L. Poliani, G. Martino, P. Panina-Bordignon, L. Adorini. 2000. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D3. Eur. J. Immunol. 30: 498-508. [Medline]
  25. Meehan, T. F., H. F. DeLuca. 2002. CD8+ T cells are not necessary for 1{alpha},25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice. Proc. Natl. Acad. Sci. USA 99: 5557-5560. [Abstract/Free Full Text]
  26. Spach, K. M., C. E. Hayes. 2005. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 175: 4119-4126. [Abstract/Free Full Text]
  27. Nashold, F. E., D. J. Miller, C. E. Hayes. 2000. 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 103: 171-179. [Medline]
  28. Bustin, S. A.. 2000. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25: 169-193. [Abstract]
  29. Spach, K. M., L. B. Pedersen, F. E. Nashold, T. Kayo, B. S. Yandell, T. A. Prolla, C. E. Hayes. 2004. Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol. Genomics 18: 141-151. [Abstract/Free Full Text]
  30. Overbergh, L., D. Valckx, M. Waer, C. Mathieu. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11: 305-312. [Medline]
  31. Khattri, R., T. Cox, S. A. Yasayko, F. Ramsdell. 2003. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4: 337-342. [Medline]
  32. Amanna, I. J., J. P. Dingwall, C. E. Hayes. 2003. Enforced bcl-xL gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J. Immunol. 170: 4593-4600. [Abstract/Free Full Text]
  33. Jung, T., U. Schauer, C. Heusser, C. Neumann, C. Rieger. 1993. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods 159: 197-207. [Medline]
  34. Hickey, W. F., K. Vass, H. Lassmann. 1992. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J. Neuropathol. Exp. Neurol. 51: 246-256. [Medline]
  35. Becher, B., B. G. Durell, A. V. Miga, W. F. Hickey, R. J. Noelle. 2001. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J. Exp. Med. 193: 967-974. [Abstract/Free Full Text]
  36. Altman, D. G.. 1991. Practical Statistics for Medical Research Chapman and Hall, London.
  37. Meehan, T. F., J. Vanhooke, J. Prahl, H. F. Deluca. 2005. Hypercalcemia produced by parathyroid hormone suppresses experimental autoimmune encephalomyelitis in female but not male mice. Arch. Biochem. Biophys. 442: 214-221. [Medline]
  38. Mizuno, T., M. Sawada, T. Marunouchi, A. Suzumura. 1994. Production of interleukin-10 by mouse glial cells in culture. Biochem. Biophys. Res. Commun. 205: 1907-1915. [Medline]
  39. Pousset, F., S. Cremona, R. Dantzer, K. Kelley, P. Parnet. 1999. Interleukin-4 and interleukin-10 regulate IL1-beta induced mouse primary astrocyte activation: a comparative study. Glia 26: 12-21. [Medline]
  40. Strle, K., J. H. Zhou, S. R. Broussard, H. D. Venters, R. W. Johnson, G. G. Freund, R. Dantzer, K. W. Kelley. 2002. IL-10 promotes survival of microglia without activating Akt. J. Neuroimmunol. 122: 9-19. [Medline]
  41. Trajkovic, V., O. Vuckovic, S. Stosic-Grujicic, D. Miljkovic, D. Popadic, M. Markovic, V. Bumbasirevic, A. Backovic, I. Cvetkovic, L. Harhaji, et al 2004. Astrocyte-induced regulatory T cells mitigate CNS autoimmunity. Glia 47: 168-179. [Medline]
  42. McGeachy, M. J., L. A. Stephens, S. M. Anderton. 2005. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 175: 3025-3032. [Abstract/Free Full Text]
  43. Fontenot, J. D., M. A. Gavin, A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330-336. [Medline]
  44. Strle, K., J. H. Zhou, W. H. Shen, S. R. Broussard, R. W. Johnson, G. G. Freund, R. Dantzer, K. W. Kelley. 2001. Interleukin-10 in the brain. Crit. Rev. Immunol. 21: 427-449. [Medline]
  45. Priller, J., A. Flugel, T. Wehner, M. Boentert, C. A. Haas, M. Prinz, F. Fernandez-Klett, K. Prass, I. Bechmann, B. A. de Boer, et al 2001. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 7: 1356-1361. [Medline]
  46. Massengale, M., A. J. Wagers, H. Vogel, I. L. Weissman. 2005. Hematopoietic cells maintain hematopoietic fates upon entering the brain. J. Exp. Med. 201: 1579-1589. [Abstract/Free Full Text]
  47. Hulshof, S., L. Montagne, C. J. De Groot, P. Van Der Valk. 2002. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 38: 24-35. [Medline]
  48. Dusso, A. S., A. J. Brown, E. Slatopolsky. 2005. Vitamin D. Am. J. Physiol. 289: F8-F28.
  49. Hayes, C. E., F. E. Nashold, K. M. Spach, L. B. Pedersen. 2003. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. 49: 277-300. [Medline]
  50. Ozenci, V., M. Kouwenhoven, Y. M. Huang, P. Kivisakk, H. Link. 2000. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-{alpha} (TNF-{alpha})- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin. Exp. Immunol. 120: 147-153. [Medline]
  51. Waubant, E., L. Gee, P. Bacchetti, R. Sloan, A. Cotleur, R. Rudick, D. Goodkin. 2001. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J. Neuroimmunol. 112: 139-145. [Medline]
  52. Rieckmann, P., M. Albrecht, B. Kitze, T. Weber, H. Tumani, A. Broocks, W. Luer, S. Poser. 1994. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 44: 1523-1526. [Abstract/Free Full Text]
  53. Musette, P., O. Benveniste, A. Lim, D. Bequet, P. Kourilsky, D. Dormont, G. Gachelin. 1996. The pattern of production of cytokine mRNAs is markedly altered at the onset of multiple sclerosis. Res. Immunol. 147: 435-441. [Medline]
  54. van Boxel-Dezaire, A. H., S. C. Hoff, B. W. van Oosten, C. L. Verweij, A. M. Drager, H. J. Ader, J. C. van Houwelingen, F. Barkhof, C. H. Polman, L. Nagelkerken. 1999. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45: 695-703. [Medline]
  55. de Jong, B. A., H. M. Schrijver, T. W. Huizinga, E. L. Bollen, C. H. Polman, B. M. Uitdehaag, M. C. Kersbergen, A. Sturk, R. G. Westendorp. 2000. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Ann. Neurol. 48: 641-646. [Medline]
  56. Martinez Doncel, A., A. Rubio, R. Arroyo, V. de las Heras, C. Martin, M. Fernandez-Arquero, E. G. de la Concha. 2002. Interleukin-10 polymorphisms in Spanish multiple sclerosis patients. J. Neuroimmunol. 131: 168-172. [Medline]
  57. Luomala, M., T. Lehtimaki, H. Huhtala, M. Ukkonen, T. Koivula, M. Hurme, I. Elovaara. 2003. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol. Scand. 108: 396-400. [Medline]



This article has been cited by other articles:


Home page
 Evid Based Complement Alternat MedHome page
A. Vojdani, F. Hebroni, Y. Raphael, J. Erde, and B. Raxlen
Novel Diagnosis of Lyme Disease: Potential for CAM Intervention
Evid. Based Complement. Altern. Med., October 15, 2007; (2007) nem138v1.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spach, K. M.
Right arrow Articles by Hayes, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spach, K. M.
Right arrow Articles by Hayes, C. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS